Higher Uric Acid in Inpatient COVID-19 Cases Ups AKI Risk
Patients with COVID-19 who had the highest quartile of serum uric acid at hospital admission had increased odds of acute kidney injury.
Kidney Week Annual Meeting
Gout Common in the US Dialysis Population
New analysis suggests that gout prevalence is 21% among patients on peritoneal dialysis and 13% among those on hemodialysis.
Urate-Lowering Therapy Not Renoprotective When Kidney Function is Normal
New findings complement previous research showing no renoprotective effect of urate-lowering therapy in patients with chronic kidney disease.
Pegloticase Effective for Uncontrolled Gout in Kidney Transplant Recipients
In a study of kidney transplant recipients treated with pegloticase for uncontrolled gout, the proportion of patients experiencing gout flares declined over the treatment period.
Gout Risk Factors, Outcomes in Dialysis Population Characterized
Some 15% of patients receiving dialysis in the United States have a gout diagnosis, according to a recent study.
Racial Disparities in Kidney Transplantation Start Downstream of Referral
Although previous studies have observed that Black patients are less likely to receive kidney transplants than White patients, the points of inequity in the transplant process were unclear.
Upacicalcet May Improve Secondary Hyperparathyroidism
The novel intravenous calcimimetic might cause fewer gastrointestinal symptoms, new research suggests.
Apabetalone Prevents CV Events in High-Risk Diabetic CKD
In the BETonMACE trial, CKD patients with type 2 diabetes who recently experienced acute coronary syndrome who received apabetalone had a significant 50% reduction in the risk for major cardiovascular events compared with placebo.
Novel Medication Relieves Pruritus in Hemodialysis Cases
Difelikefalin, an investigational intravenous drug, improved moderate to severe itching compared with placebo in patients on hemodialysis, according to phase 3 trial results.
Finerenone Slows CKD Progression in Diabetic Kidney Disease
Finerenone vs placebo added to standard therapy was associated with a significant 18% reduction in the risk for major adverse kidney events in patients with both chronic kidney disease and type 2 diabetes mellitus.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Kidney Week 2020 Reimagined
Loading... 
Loading...